Interspecies scaling: Predicting clearance of drugs in humans. Three different approaches

Xenobiotica

Volumn 26, Issue 9, 1996, Pages 887-895

  Mahmood, I ^a   Balian, J D ^b  

^a Woodmont Office Center II   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIVICIN; CAFFEINE; CEFAZOLIN; CEFMETAZOLE; CEFOPERAZONE; CEFOTETAN; CEFTIZOXIME; CISPLATIN; CYCLOSPORIN; DIAZEPAM; DRUG; ERYTHROMYCIN; LATAMOXEF; NORFLOXACIN; OLEANDOMYCIN; PEFLOXACIN; PHENAZONE; PHENCYCLIDINE; PHENYTOIN; PROCATEROL; PROGABIDE; PROPRANOLOL; QUINIDINE; THEOPHYLLINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN; ZENARESTAT; ZONISAMIDE;

ARTICLE; BODY WEIGHT; BRAIN WEIGHT; DRUG CLEARANCE; HUMAN; LIFESPAN; NONHUMAN; PREDICTION; SPECIES DIFFERENCE; TECHNIQUE;

ANIMALIA;

EID: 0029828960     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259609052491     Document Type: Article

References (41)

1. BACHMANN, K., 1989, Predicting toxiokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. Journal of Applied Toxicology, 9, 331-338.
2. BIALER, M., 1993, Comparative pharmacokinetics of the newer antiepileptic drugs. Clinical Pharmacokinetics, 6, 441-452.
3. BONATI, M., LATINI, R., and TOGNONI, G., 1984-85, Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug Metabolism Reviews, 15, 1355-1383.
4. BOXENBAUM, H., and FERTIG, J. B., 1984, Scaling of antipyrine intrinsic clearance of unbound drug on 15 mammalian species. European Journal of Drug Metabolism and Pharmacokinetics, 9, 177-183.
5. BOXENBAUM, H., MURRAY, W., MARKIN, R., and CIRAULO, D., 1985, In Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs, edited by G. Barnett, and C. C. Nora (Forest City, California: Biomedical Publications), p. 93.
6. BOXENBAUM, H., 1980, Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmacy, 8, 165-176.
7. BOXENBAUM, H., and DILEA, C., 1975, First-time-in-human dose selection: Allometric thoughts and perspectives. Journal of Clinical Pharmacology, 35, 957-966.
8. BRAZELL, R. K., PASK, Y. H., WOOLRIDGE, C. B., MCCUE, B., BASKER, R., COUCH, R., and YORK, B., 1990, Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors. Drug Metabolism Dispersion, 18, 435-440.
9. COOK, C. S., ROZEK, L. F., STOLZENBACH, J., ANDERSON, S., SCHOENHARD, G. L., and KASION, A., 1993, Pharmacokinetics of a novel antiarrhythmic drug, actisomide. Pharmaceutical Research, 10, 427-433.
10. CRUZE, C. A., KELM, G. R., and MEREDITH, M. P., 1995, Interspecies scaling of tebufelone pharmacokinetic data and application to preclinical toxicology. Pharmaceutical Research, 12, 895-901.
11. DUTHU, G. S., 1985, Interspecies correlation of the pharmacokinetics of erythromycin, oleandomycin, and tylosin. Journal of Pharmaceutical Sciences, 74, 943-946.
12. ELDON, M. A., BATTLE, M. M., COON, M. J., NORDBLOM, G. D., SEDMEN, A. J., and COLBURN, W. A., 1993, Clinical pharmacokinetics and relative bioavailability of oral procaterol. Pharmaceutical Research, 10, 603-605.
13. EL SAYED, M. A., LOSCHER, W., and FREY, H. H., 1978, Pharmacokinetics of ethosuximide in the dog. Archives in International Pharmacodynamics, 234, 180-192.
14. EVANS, G. H., NIES, A. S., and SHAUD, D. G., 1973, The disposition of propranolol. III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. Journal of Pharmacology and Experimental Therapeutics, 186, 114-122.
15. GASCON, R. A., CALVO, B., HERNANDEZ, R. M., DOMINGUEZ-GIL, A., and PEDRAZ, J., 1994, Interspecies scaling ot cimetidine-theophylline pharmacokinetic interaction : Interspecies scaling in pharmacokinetic interaction. Pharmaceutical Research, 11, 945-950.
16. GOODMAN GILMAN, A., RALL, T. W., NIES, A. S., and TAYLOR, P., (eds), 1993, Goodman and Gilman's, The Pharmacological basis of Therapeutics, eighth edition (New York: McGraw-Hill, Inc), pp. 1674 and 1680.
17. GUENTERT, T. W., HUANG, J. D., and QIE, S., 1982, Disposition of quinidine in the rabbit. Journal of Pharmaceutical Sciences, 71, 812-815.
18. HEUSNER, A. A., 1987, What does the power function reveal about structure and function in animal of different size. Annual Reviews in Physiology, 78, 121-133.
19. ISHIGAMI, M., SABUROMANI, K., NIINO, K., KIDO, M., MORITA, S., MIYAMOTO, G., and KOHN, H., 1979, Pharmacokinetics of procaterol in the rat, rabbit and beagle dog. Arzneimittelforschung, 29, 266-270.
20. IVEN, H., 1977, The pharmacokinetics and organ distribution of ajmaline and quinidine in the mouse. Naumyn-Schmiedberg's Archives in Pharmacology, 298, 43-50.
21. KAWAKAINI, J., YAMAMOTO, K., SWADA, Y., and IGA, T., 1994, Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data. Journal of Pharmacokinetics and Biopharmacy, 22, 207-227.
22. KING, F. G., DEDRICK, R. L., and FARRIS, F. F., 1986, Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum (II) (DDP) in several species. Journal of Pharmacokinetics and Biopharmacy, 14, 131-155.
23. KLOTZ, V., ANTONIN, K. H., and BIECK, P. R., 1976, Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. Journal of Pharmacology and Experimental Therapeutics, 199, 67-73.
24. LEVY, R. H., DREIFUSS, F. F., MATTSON, R. H., MELDRUM, B., and PENRY, J. K. (eds), 1989, Antiepileptic Drugs, 3rd edition (New York: Raven Press).
25. LEVY, R. H., PITLICK, W. H., EICHELBAUM, M., and MEIJER, J. (eds), 1984, Metabolism of Antiepileptic Drugs (New York: Raven Press).
26. LOSCHER, W. 1978, Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. Journal of Pharmacology and Experimental Therapeutics, 204, 255-261.
27. MAHMOOD, I., and BALIAN, J. D., 1996, Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. Journal of Pharmaceutical Sciences, 85, 411-414.
28. 11C]methyl)-1,2-benzisoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in men. Arzneimittelforschung, 33, 961-967.
29. MCGOVERN, J. P., WILLIAMS, M. G., and STEWART, J. C., 1988, Interspecies comparison of acivicin pharmacokinetics. Drug Metabolism and Disposition, 16, 18-22.
30. MCNAMARA, P. J., 1991, Interspecies scaling in pharmacokinetics. In Pharmaceutical Bioequivalence, edited by Peter G. Welling, Francis L. S. Tse, and Shrikant V. Dighe (New York: Marcel Dekker Inc).
31. MONTAY, G., GOUEFFON, Y., and ROOQUET, F., 1984, Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrobial Agents and Chemistry, 25, 463-472.
32. MORDENTI, J., 1985, Pharmacokinetic scale up: accurate prediction of human pharmacokinetic profiles from animal data. Journal of Pharmaceutical Sciences, 74, 1097-1099.
33. OWENS, S. M., HARDWICK, W. C., and BLACKALL, D., 1987, Phencyclidine pharmacokinetic scaling among species. Journal of Pharmacology and Experimental Therapeutics, 242, 96-101.
34. PAXTON, J. W., KIM, S. N., and WHITFIELD, L. R., 1990, Pharmacokinetic and toxicity of the antitumor agents amascrine and CI-921, a new analogue, in mice, rats, rabbits, dogs and humans. Cancer Research, 50, 2692-2697.
35. SACHER, G., 1959, Relation of lifespan to brain weight and body weight in mammals. In CIBA Foundation Colloquia on Aging, edited by G. E. W. Wolstenholme and M. O'Connor (London: Churchill), pp. 115-133.
36. SANGAILI, L., BORTOLLOTTI, A., JIRITANO, L., and BONATI, M., 1988, Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. Drug Metabolism and Disposition, 16, 749-753.
37. STREETER, A. J., 1995, Dept of Drug Metabolism, The R. W. Johnson Pharmaceutical Research Institute, Spring House, PA 10477. Personal communication.
38. SWADA, Y., HANANO, M., SUGIYAMA, Y., and IGA, T., 1984, Prediction of the disposition of β-lactam antibiotics in humans from phari-nacokinetic parameters in animals. Journal of Pharmacokinetics and Biopharmacy, 12, 241-261.
39. SWADA, Y., HANANO, M., SUGIYAMA, Y., and IGA, T., 1985, Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. Journal of Pharmacokinetics and Biopharmacy, 13, 477-492.
40. TANAKA, Y., SHIMOJYO, H., HATA, T., HASHIMOTO, M., and NOGUCHI, H., 1994, Toxicokinetrics of zenarestat, an aldose reductase inhibitor in animals and man. Xenobiotica, 5, 461-471.
41. UEDA, C. T., BALLARD, B. E., and ROWLAND, M., 1977, Concentration-time effects on quinidine disposition kinetics in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics, 200, 459-468.